Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 3/20 | 1.00 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | FLT3 | P36888 | 1/20 | 0.48 |
| ▸ | APP | P05067 | 1/20 | 0.47 |
| ▸ | TYR | P14679 | 1/20 | 0.47 |
| ▸ | DAO | P14920 | 1/20 | 0.47 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | PIM1 | P11309 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | MAOB | P27338 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9956377 | 1.00 | CYP2A6 (1.00) | CYP2A6RAB9ANPC1MAPK1MAPT | |
| SCHEMBL29502957 | 1.00 | CYP2A6 (1.00) | CYP2A6RAB9ANPC1MAPK1MAPT | |
| Acetaldehyde SCHEMBL6272809 | 0.94 | CYP2A6 (0.89) | CYP2A6RAB9ANPC1MAPK1MAPT | |
| Benzofuran SCHEMBL5030477 | 0.88 | CYP2A6 (0.77) | CYP2A6RAB9ANPC1MAPK1MAPT | |
| SCHEMBL28487808 | 0.85 | CYP2A6 (0.72) | CYP2A6RAB9ANPC1MAPK1MAPT | |
| SCHEMBL8038555 | 0.80 | CYP2A6 (0.67) | CYP2A6RAB9ANPC1MAPK1MAPT | |
| SCHEMBL8038562 | 0.80 | CYP2A6 (0.67) | CYP2A6RAB9ANPC1MAPK1MAPT | |
| SCHEMBL27757855 | 0.79 | CYP2A6 (0.62) | CYP2A6RAB9ANPC1MAPK1MAPT | |
| SCHEMBL17185672 | 0.78 | CYP2A6 (0.64) | CYP2A6RAB9ANPC1MAPK1MAPT | |
| SCHEMBL225144 | 0.78 | CYP2A6 (0.64) | CYP2A6RAB9ANPC1MAPK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1821 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250280857-A1 | DEGRADATION-RESISTANT ALDEHYDE-CONTAINING COMPOSITIONS | ZOOMESSENCE INC (US) | 2025-09-11 | — | — | US | claimed |
| CN-119136683-A | Degradation resistant aldehyde-containing compositions | 祖姆森斯有限公司 | 2024-12-13 | — | — | CN | claimed |
| CN-118684596-A | 2-Imine-3-carbonyl-propionamide compound, and preparation method and application thereof | 上海大学 | 2024-09-24 | — | — | CN | claimed |
| CN-117700310-A | Synthesis method of aromatic aldehyde compound or deuterated aromatic aldehyde compound | 五邑大学 | 2024-03-15 | — | — | CN | claimed |
| CN-117362162-A | Preparation method of carbonyl compound | 中国科学院大连化学物理研究所 | 2024-01-09 | — | — | CN | claimed |
| WO-2023215706-A1 | DEGRADATION-RESISTANT ALDEHYDE-CONTAINING COMPOSITIONS | ZoomEssence, Inc. (US) | 2023-11-09 | — | — | WO | claimed |
| CN-113735769-B | Quinolinone alkaloid derivative containing acylhydrazone structure at 3-position and preparation method and application thereof | 太原理工大学 | 2023-02-28 | — | — | CN | claimed |
| CN-115125552-B | Synthesis method of tertiary phosphine compound | 江苏欣诺科催化剂股份有限公司 | 2022-11-22 | — | — | CN | claimed |
| CN-115125552-A | Synthesis method of tertiary phosphine compound | 江苏欣诺科催化剂股份有限公司 | 2022-09-30 | — | — | CN | claimed |
| US-11427596-B2 | Metal-free solvent-free synthesis of fused-pyrido heterocycles and biomedical applications | Indian Institute of Technology Indore (IN) | 2022-08-30 | — | — | US | claimed |
| WO-2001019796-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2001-03-22 | — | — | WO | claimed |
| WO-2001000594-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION BIOSCIENCE AG (DE) | 2001-01-04 | — | — | WO | claimed |
| EP-0957093-A2 | Retrovial protease inhibitors | MONSANTO COMPANY (US) | 1999-11-17 | — | — | EP | claimed |
| US-5643924-A | Retroviral protease inhibitors | MONSANTO COMPANY OF ST. LOUIS (US) | 1997-07-01 | — | — | US | claimed |
| EP-0641325-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1995-03-08 | — | — | EP | claimed |
| WO-1993023379-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1993-11-25 | — | — | WO | claimed |
| US-4380629-A | Styryl-like compounds showing a color-developing and bleaching behavior with improved stability and prolonged lifetime | MATSUSHITA ELECTRIC INDUSTRIAL COMPANY, LIMITED (JP) | 1983-04-19 | — | — | US | claimed |
| US-4314058-A | Indolins styryl-like compounds | MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) | 1982-02-02 | — | — | US | claimed |
| EP-0007824-B1 | BENZOFURANE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THERAPEUTIC COMPOSITION CONTAINING THEM. | LABORATOIRES JACQUES LOGEAIS Société dite: (FR) | 1981-07-22 | — | — | EP | claimed |
| US-4147862-A | Method of preparing styryl-like compounds | MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) | 1979-04-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11427596-B2 | Metal-free solvent-free synthesis of fused-pyrido heterocycles and biomedical applications | SLC11A2, WEE1, BRCA1 | CYP2A6 2848/4885RAB9A 2878/4885NPC1 4616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.